A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiujuan, Tang, Peng, Li, Shifei, Wang, Shushu, Liang, Yueyang, Zhong, Ling, Ren, Lin, Zhang, Ting, Zhang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827032/
https://www.ncbi.nlm.nih.gov/pubmed/29483583
http://dx.doi.org/10.1038/s41467-018-03210-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827032/
https://www.ncbi.nlm.nih.gov/pubmed/29483583
http://dx.doi.org/10.1038/s41467-018-03210-2

Ejemplares similares